181 related articles for article (PubMed ID: 23256603)
1. Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.
Paul F
Expert Opin Pharmacother; 2013 Jan; 14(1):1-3. PubMed ID: 23256603
[No Abstract] [Full Text] [Related]
2. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Li H; Zhang X
N Engl J Med; 2010 May; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
[No Abstract] [Full Text] [Related]
3. An update on cladribine for relapsing-remitting multiple sclerosis.
Holmøy T; Torkildsen Ø; Myhr KM
Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
[TBL] [Abstract][Full Text] [Related]
4. Cladribine for multiple sclerosis.
Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
[TBL] [Abstract][Full Text] [Related]
5. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
Sipe JC
Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
[TBL] [Abstract][Full Text] [Related]
6. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Mann H
N Engl J Med; 2010 May; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
[No Abstract] [Full Text] [Related]
7. COVID-19 in Cladribine-treated patient with multiple sclerosis.
Haham N; Vaknin-Dembinsky A
J Neuroimmunol; 2021 Oct; 359():577690. PubMed ID: 34390951
[TBL] [Abstract][Full Text] [Related]
8. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
[No Abstract] [Full Text] [Related]
9. Cladribine (Mavenclad) for multiple sclerosis.
Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
[No Abstract] [Full Text] [Related]
10. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
12. Oral therapy for multiple sclerosis--sea change or incremental step?
Carroll WM
N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
[No Abstract] [Full Text] [Related]
13. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
15. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL
Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909
[TBL] [Abstract][Full Text] [Related]
16. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
[TBL] [Abstract][Full Text] [Related]
17. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
Afolabi D; Albor C; Zalewski L; Altmann DR; Baker D; Schmierer K
Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
[TBL] [Abstract][Full Text] [Related]
18. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
Rejdak K; Stelmasiak Z; Grieb P
Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
[TBL] [Abstract][Full Text] [Related]
19. Cladribine: mode of action and implications for treatment of multiple sclerosis.
Leist TP; Weissert R
Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
